Q4 FY26 Results (April 2026)
Expected: 2026-04-01/2026-04-30HIGH confidence
Record full-year margins to validate sustainability of 35%+ operating profit
“Three consecutive quarters of margin expansion with Q3 at 35.66% (highest in 12 quarters)”
Glaxosmithkline Pharmaceuticals Ltd: Is It a Deep Value Opportunity?
AverageSteady Growth
As of Mar 28, 2026, Glaxosmithkline Pharmaceuticals Ltd (Pharma - MNC bulk Drugs) has a deep value score of 48/100 (rated Average). Earnings are accelerating. 1Y return vs Nifty 500: -19%.
Strong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
📊Debt increased 260% YoY — leverage rising
💰Trading 52% above estimated fair value — significant premium
Re-Rating Catalysts
1. Q4 FY26 Results (April 2026)
2026-04-01/2026-04-30HIGH
2. Strategic Portfolio Review Completion (June 2026)
2026-06-01/2026-06-30MEDIUM
3. New Product Launch Pipeline (July 2026)
2026-07-01/2026-07-30MEDIUM
Value Trap Risks
1. Regulatory Risk
HIGH2. Portfolio Limitations
MEDIUM3. Parent Company Strategy
MEDIUMKey Numbers
PAT Growth YoY
+29%
Stable
Revenue YoY
+10%
Stable
Operating Margin
36.0%
+500 bps YoY
PE Ratio
38.1
PEG Ratio
1.32
Current Price
₹2,260
Dividend Yield
1.86%
3Y PAT CAGR
-18%
Market Cap
38.3K Cr
Valuation
Significantly OvervaluedIs Glaxosmithkline Pharmaceuticals Ltd a Turnaround Opportunity?
Deep value thesis based on recent earnings • Updated Mar 28, 2026
Margin-led turnaround with record 35.66% operating margins and first ₹1,000+ crore revenue quarter signaling sustainable profitability ahead of industry recovery.
Verdict
TURNAROUND_IN_PROGRESS
What Could Re-Rate Glaxosmithkline Pharmaceuticals Ltd?
Re-rating catalysts over the next 2-4 quarters • Updated Mar 28, 2026
Strategic Portfolio Review Completion (June 2026)
Expected: 2026-06-01/2026-06-30MEDIUM confidence
Potential divestment of non-core assets to unlock ₹500-700 crore value
“Company's strong cash position of ₹2,426 crore and focus on portfolio optimization”
New Product Launch Pipeline (July 2026)
Expected: 2026-07-01/2026-07-30MEDIUM confidence+₹150 Cr revenue
3-4 specialty drugs expected to drive 15%+ volume growth in H2 FY27
Impact: +₹150 Cr revenue
“Management commentary on strategic focus on innovation and specialty products”
Share Buyback Announcement (Q1 FY27)
Expected: 2026-07-01/2026-09-30MEDIUM confidence
Management likely to deploy ₹500+ crore from strong cash position
“Cash balance of ₹2,426 crore with limited capital expenditure requirements”
What Are the Value Trap Risks for Glaxosmithkline Pharmaceuticals Ltd?
Risks that could prevent re-rating or deepen the value trap
Regulatory Risk
HIGHGovernment announcement of price caps on essential medicines
Impact: -800 bps margin impact
Management view: Management stated implementation of new Labour Codes had no material impact, suggesting preparedness for regulatory changes
Monitor: Quarterly price realization data for essential drug portfolio
Portfolio Limitations
MEDIUMFailure to launch 3+ specialty drugs by Q3 FY27
Impact: -500 bps margin impact
Management view: Management highlighted strategic focus on innovation and portfolio diversification
Monitor: New product launch cadence and market share in specialty segments
Parent Company Strategy
MEDIUMAnnouncement of stake reduction by parent company
Management view: Parent company continues to support Indian operations as key growth market
Monitor: Changes in intercompany transactions and R&D collaboration
What Is Glaxosmithkline Pharmaceuticals Ltd's Management Guidance?
Forward-looking targets from management for FY27
Revenue Growth Target
8%
Implied PAT Growth
25%
OPM Guidance
35%
Capex Plan
₹50 Cr
Management Tone: CAUTIOUS
Key Milestones
• Completion of strategic portfolio review by June 2026
• Launch of 3-4 specialty drugs by September 2026
• Potential share buyback announcement in Q1 FY27
How Fast Is Glaxosmithkline Pharmaceuticals Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +10% | +5% | Stable |
| PAT (Net Profit) | +29% | -18% | Stable |
| OPM | 36.0% | +500 bps | Volatile |
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Mar 28, 2026.
Frequently Asked Questions: Glaxosmithkline Pharmaceuticals Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Glaxosmithkline Pharmaceuticals Ltd's deep value score?
Glaxosmithkline Pharmaceuticals Ltd has a deep value score of 48/100 (rated Average). This score is calculated from three components
- Earnings Score: 24/40 — measures PAT growth momentum across quarters
- Underperformance Score: 11/35 — how much the stock trails Nifty 500 (deeper underperformance = higher contrarian signal)
- Quality Score: 25/25 — operational quality (margins, revenue growth, valuation)
Is Glaxosmithkline Pharmaceuticals Ltd fundamentally improving?
Glaxosmithkline Pharmaceuticals Ltd's quarterly profit (PAT) growth trajectory
- Latest Quarter PAT Growth (QoQ): +15%
- Previous Quarter PAT Growth (QoQ): +26%
- 2 Quarters Ago PAT Growth (QoQ): -22%
- PAT Acceleration: +18.4pp (profits are accelerating)
- 2 consecutive quarters of positive PAT growth
Why is Glaxosmithkline Pharmaceuticals Ltd underperforming despite good earnings?
Glaxosmithkline Pharmaceuticals Ltd is underperforming the market despite improving earnings — this is the core deep value thesis
- 1-Year Return vs Nifty 500: -19%
- 6-Month Return vs Nifty 500: -8%
- 3-Month Return vs Nifty 500: +3%
- Yet average quarterly PAT growth is +6% — earnings are improving
- The market often takes time to re-rate stocks with improving fundamentals. This gap between price performance and earnings improvement is what deep value research seeks to identify.
What is the earnings momentum for Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd's earnings momentum is Steady — consistent growth.
- PAT QoQ progression: -22% → +26% → +15% (2Q ago → 1Q ago → latest)
- Acceleration: +18.4pp
- PAT YoY Growth: +29%
Is Glaxosmithkline Pharmaceuticals Ltd undervalued?
Glaxosmithkline Pharmaceuticals Ltd's valuation metrics
- Price-to-Earnings (PE): 38.1x
- Price-to-Book (PB): 22.4x
- PEG Ratio: 1.3x
- Margin of Safety: -52% (appears overvalued)
What are the revenue and margin trends for Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd's revenue and margin trends
- Latest Quarter Revenue Growth (QoQ): +6%
- Average Quarterly Revenue Growth: +4%
- Revenue Acceleration: +11.8pp
- Latest OPM Change: +1.4pp (margins expanding)
- Average OPM Change: +0.5pp
- Revenue YoY: +10%
What is Glaxosmithkline Pharmaceuticals Ltd's trailing twelve month (TTM) performance?
Glaxosmithkline Pharmaceuticals Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹1,000 Cr
- TTM PAT Growth: +19.0% YoY
- TTM Revenue: ₹4,000 Cr
- TTM Revenue Growth: +2.6% YoY
- TTM Operating Margin: 33.9%
What sector does Glaxosmithkline Pharmaceuticals Ltd belong to?
Glaxosmithkline Pharmaceuticals Ltd key facts
- Sector: Pharma - MNC bulk Drugs
- Market Cap: ₹38.3K Cr
- Rank in Pharma - MNC bulk Drugs: #1 by value score
- Overall rank among all deep value stocks: #36
Is Glaxosmithkline Pharmaceuticals Ltd a good deep value opportunity to study?
Glaxosmithkline Pharmaceuticals Ltd shows limited deep value signals currently — score is 48/100 (Average). Monitor for improvement.
- Value Score: 48/100 (Average)
- Earnings: Accelerating
- 1Y Underperformance: -19% vs Nifty 500
What is the bull and bear case for Glaxosmithkline Pharmaceuticals Ltd?
Research Signals (Bull Case)
- Earnings accelerating — profit growth speeding up
- 2 consecutive quarters of positive PAT growth
- Revenue growth also accelerating
- Operating margins expanding
Risk Factors (Bear Case)
- Appears overvalued despite underperformance
How does the Pharma - MNC bulk Drugs sector look for deep value?
Pharma - MNC bulk Drugs deep value sector overview
- 1 deep value stocks in this sector
- Average value score: 48/100
- Avg PAT acceleration: +18.4pp
- Top pick: Glaxosmithkline Pharmaceuticals Ltd
What is deep value investing?
Deep value investing studies stocks that are underperforming the market despite showing improving fundamentals. The thesis is that the market has not yet recognized the earnings recovery, creating a potential valuation gap. It requires patience — recovery can take several quarters.
How is the deep value score calculated?
The deep value score (0-100) combines three factors:
- Earnings (0-40 pts): PAT growth across last 3 quarters, acceleration, and consecutive growth - Underperformance (0-35 pts): How much the stock trails Nifty 500 over 1Y, 6M, 3M (deeper underperformance = higher score) - Quality (0-25 pts): Revenue growth, margin trends, and valuation metrics (PEG, P/B)
Higher score indicates a stronger contrarian research signal.
What are the growth catalysts for Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd has 4 key growth catalysts identified from recent earnings analysis
- Q4 FY26 Results (April 2026)
- Strategic Portfolio Review Completion (June 2026)
- New Product Launch Pipeline (July 2026)
- Share Buyback Announcement (Q1 FY27)
What are the key risks in Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd has 3 key risks worth monitoring
- Regulatory Risk
- Portfolio Limitations
- Parent Company Strategy
The above FAQs are generated from publicly available earnings data. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.